Abstract: Disclosed are virtual reality systems, in particular immersive virtual reality systems, their parts, construction and use. The systems and/or parts thereof may be used by adults or children, and may be adapted to support, often within a single device, a large range of users of different sizes and medical condition. Users with physical disabilities have difficulties using existing immersive technologies such as those using accessories like head-mounted displays and data gloves. Such users are provided with immersive virtual reality outputs that allow them to see virtual representations of their body parts which appear in a correct spatial position relative to the users' viewpoint.

Abstract: Disclosed are virtual reality systems, in particular immersive virtual reality systems, their parts, construction and use. The systems and/or parts thereof may be used by adults or children, and may be adapted to support, often within a single device, a large range of users of different sizes and medical condition. Users with physical disabilities have difficulties using existing immersive technologies such as those using accessories like head-mounted displays and data gloves. Such users are provided with immersive virtual reality outputs that allow them to see virtual representations of their body parts which appear in a correct spatial position relative to the users' viewpoint.

Abstract: A therapeutic composition and method for the treatment of cancer comprising an arginine decomposing enzyme, particularly an arginine decarboxylase that is a biosynthetic arginine decarboxylase of E. Coli and modifications thereof, and may be PEG-ilated. The therapeutic composition may contain essential co-factors of said arginine decomposing enzyme, protein breakdown inhibitors such as insulin, insulin-like growth factors, IGF-I, IGF-II, growth hormones, protein breakdown inhibiting peptide aldehydes such as Cbz-Leu-Leu-Leucinal, or lactacystin, and glucose, all of which can be admixed with the arginine decomposing enzyme or may be maintained apart from and separately administered from the arginine decomposing enzyme. The therapeutic composition can be administered intravenously, intraperitoneally, intramuscularly, intraventricularly, nasally, extracorporeally or orally.

Abstract: A therapeutic composition and method for the treatment of cancer comprising an arginine decomposing enzyme, particularly an arginine decarboxylase that is a biosynthetic arginine decarboxylase of E. coli and modifications thereof, and may be PEG-ilated. The therapeutic composition may contain essential co-factors of said arginine decomposing enzyme, protein breakdown inhibitors such as insulin, insulin-like growth factors, IGF-I, IGF-II, growth hormones, protein breakdown inhibiting peptide aldehydes such as Cbz-Leu-Leu-Leucinal, or lactacystin, and glucose, all of which can be admixed with the arginine decomposing enzyme or may be maintained apart from and separately administered from the arginine decomposing enzyme. The therapeutic composition can be administered intravenously, intraperitoneally, intramuscularly, intraventricularly, nasally, extracorporeally or orally.

Abstract: Method, compositions and apparatus for the treatment of tumors by systemic deprivation of an essential amino acid, preferably of arginine, by extracorporeal treatment of the patient's blood characterized by molecular exchange between the blood and a dialyzing fluid which contains most of the essential low-molecular substances found in blood plasma with the exception of at least one of the essential amino acids. The release of muscular protein amino acids can be limited by use of an insulin/glucose clamp. The treatment process can be used in conjunction with chemotherapy.